Gerd Ritter
Scientist
Ludwig Institute’s IP Office, New York
Ludwig Institute for Cancer Research
Australia
Biography
I joined the New York Branch of the Ludwig Institute for Cancer Research, based at Memorial Sloan-Kettering Cancer Center, in 1994. My research at Ludwig has bridged laboratory, pre-clinical and early phase clinical development of antibody- and vaccine-based human cancer immunotherapies, in cooperation with Ludwig’s clinical trials management and intellectual property teams. In 2013, I joined the Ludwig technology development program as the developmental research director. I received my PhD in human biology from the University of Marburg, Germany, trained as a postdoctoral fellow in human cancer immunology at Memorial-Sloan-Kettering Cancer Center in New York, was a research group leader in immunology at Fidia Research Laboratories, a pharmaceutical company in Abano Terme, Italy, and previously held a faculty position at Weill Cornell Medical College.
Research Interest
Developmental research, clinical trials, immunotherapy, technology development
Publications
-
Livingston, Philip O., et al. "Improved survival in stage III melanoma patients with GM2 antibodies: a randomized trial of adjuvant vaccination with GM2 ganglioside." Journal of Clinical Oncology 12.5 (1994): 1036-1044.
-
Sato, Eiichi, et al. "Intraepithelial CD8+ tumor-infiltrating lymphocytes and a high CD8+/regulatory T cell ratio are associated with favorable prognosis in ovarian cancer." Proceedings of the National Academy of Sciences of the United States of America 102.51 (2005): 18538-18543.
